Cargando…
Enhancement of anti-tumor efficacy of immune checkpoint blockade by alpha-TEA
Cancer immunotherapy such as anti-PD-1/anti-PD-L1 immune checkpoint blockade (ICB) can provide significant clinical benefit in patients with advanced malignancies. However, most patients eventually develop progressive disease, thus necessitating additional therapeutic options. We have developed a no...
Autores principales: | Redmond, William L., Kasiewicz, Melissa J., Akporiaye, Emmanuel T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9992800/ https://www.ncbi.nlm.nih.gov/pubmed/36911733 http://dx.doi.org/10.3389/fimmu.2023.1057702 |
Ejemplares similares
-
Editorial: Combinatorial Approaches to Enhance Anti-tumor Immunity: Focus on Immune Checkpoint Blockade Therapy
por: Andersson, Patrik, et al.
Publicado: (2019) -
The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
por: Petitprez, Florent, et al.
Publicado: (2020) -
MCT4 blockade increases the efficacy of immune checkpoint blockade
por: Babl, Nathalie, et al.
Publicado: (2023) -
Targeting Myeloid-Derived Suppressor Cells to Enhance the Antitumor Efficacy of Immune Checkpoint Blockade Therapy
por: Li, Xueyan, et al.
Publicado: (2021) -
Editorial: Factors determining long term anti-tumor responses to immune checkpoint blockade therapy
por: Zappasodi, Roberta, et al.
Publicado: (2022)